S/GSK1349572

Brand

Abbexa

Description

S/GSK1349572 (GSK1349572, Dolutegravir) is a novel potent inhibitor of HIV integrase with an IC50 of 2.7 nM in vitro. Dolutegravir (DTG, GSK1349572) is metabolized primarily by uridine diphosphate glucuronyltransferase (UGT)1A1, with a minor role of cytochrome P450 (CYP)3A, and with renal elimination of unchanged drug being extremely low (< 1% of the dose). S/GSK1349572 is a next generation integrase inhibitor (INI) with low nM potency. Susceptibility to S/GSK1349572 and raltegravir (RAL) was determined for INI resistant clinical isolates from therapy experienced patients treated with RAL plus optimized background regimen.

Application

Reactivity

Photos